# 508277891 12/12/2023

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT8325080

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
AMPLYX PHARMACEUTICALS, INC.	11/13/2023

#### **RECEIVING PARTY DATA**

Name:	BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL
Street Address:	HEGENHEIMERMATTWEG 167B
City:	ALLSCHWIL
State/Country:	SWITZERLAND
Postal Code:	4123

## **PROPERTY NUMBERS Total: 6**

Property Type	Number
Application Number:	16770476
Application Number:	17934629
Application Number:	17271020
Application Number:	17908079
Application Number:	18002012
Application Number:	17253885

#### **CORRESPONDENCE DATA**

**Fax Number:** (973)596-0545

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** 973-596-4500

Email: IPDocket@gibbonslaw.com
Correspondent Name: IP DOCKET ADMINISTRATOR
Address Line 1: ONE GATEWAY CENTER

Address Line 2: GIBBONS P.C.

Address Line 4: NEWARK, NEW JERSEY 07102

ATTORNEY DOCKET NUMBER:	104610-110195
NAME OF SUBMITTER:	XIANGJING ZHAN
SIGNATURE:	/Xiangjing Zhan/
DATE SIGNED:	12/12/2023

PATENT 508277891 REEL: 065843 FRAME: 0001

# **Total Attachments: 20**

source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page1.tif source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page2.tif source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page3.tif source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page4.tif source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page5.tif source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page6.tif source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page7.tif source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page8.tif source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page9.tif source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page10.tif source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page11.tif source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page12.tif source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page13.tif source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page14.tif source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page15.tif source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page16.tif source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page17.tif source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page18.tif source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page19.tif source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page20.tif

### ASSIGNMENT OF REGISTERED INTELLECTUAL PROPERTY

THIS ASSIGNMENT OF REGISTERED INTELLECTUAL PROPERTY (this "Assignment") is entered into as of 13 November, 2023 by and between Amplyx Pharmaceuticals, Inc., a Delaware corporation ("Assignor") with its principal place of business at 66 Hudson Boulevard East New York, NY 10001-2192, United States of America and Basilea Pharmaceutica International AG, Allschwil, a Swiss Corporation ("Assignee") with its principal place of business at Hegenheimermattweg 167b, 4123 Allschwil, Switzerland. Except as otherwise defined herein, capitalized terms used in this Assignment shall have the meaning ascribed to them in the Asset Purchase Agreement dated as of 13 November, 2023 (the "Purchase Agreement"), by and among Assignor, Assignee, and the other parties named therein.

**WHEREAS**, pursuant to the Purchase Agreement, Assignor and the Transferring Affiliates have agreed to sell, convey, assign, transfer and deliver the Purchased Assets to Assignee;

WHEREAS, the Purchased Assets include certain items of Intellectual Property; and

**WHEREAS**, in accordance with the Purchase Agreement, Assignor desires to sell, convey, assign, transfer and deliver to Assignee, and Assignee desires to accept such sale, conveyance, assignment, transfer and delivery of all of Assignor's worldwide right, title and interest in and to the patent applications and patents set forth on Schedule A attached hereto (the "*Purchased Patents*").

**NOW, THEREFORE**, in exchange for the consideration set forth in the Purchase Agreement and the mutual covenants contained herein and in the Purchase Agreement, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:

- 1. Assignor does hereby sell, convey, assign, transfer and deliver to Assignee, and Assignee hereby accepts such sale, conveyance, assignment, transfer and delivery of all of Assignor's worldwide right, title and interest in and to:
  - (a) the Purchased Patents; and
- (b) the right (whether at law, in equity, by contract or otherwise) to enjoy or otherwise exploit any of the Purchased Patents, including all rights to sue for past, current or future infringement or misappropriation of, or damage or injury to, any of (a) the Purchased Patents, whether known or unknown and whether arising before or after the date of this Assignment, and (b) any continuations, divisions, reissues, reexaminations, registrations, renewals and extensions (including supplementary protection certificates and the like) of any such Purchased Patents that may hereafter be secured by Assignee under the Laws now or hereafter in effect in the United States and worldwide.
- 2. The Purchased Patents and all right, title and interest in and to the same are to be held and enjoyed by the Assignee, its successors and assigns from and after the date hereof as fully and entirely as the same would have been held and enjoyed by the Assignor had this Assignment not been made.
- 3. Assignor agrees to execute all documents necessary to perfect such right, title, and interest in and to Assignee, its successors, assigns, and legal representatives. In the event that Assignor is unable to fully perform its obligations under this Section 3, Assignor hereby irrevocably designates and appoints Assignee or its assigns and their duly authorized officers and agents as Assignor's agents and attorneys-infact to act for and in Assignor's behalf and instead of Assignor, to execute and file any registration, application or other document and to do all other lawfully permitted acts in connection with the Purchased

Patents assigned to Assignee hereunder. The foregoing appointment is deemed a power coupled with an interest and is irrevocable.

4. The terms of the Purchase Agreement, including, but not limited to, Assignor's representations, warranties, covenants, agreements and indemnities relating to the Purchased Patents, are incorporated herein by this reference. Nothing in this Assignment shall, or shall be deemed to, modify, expand, supersede or otherwise affect any provisions of the Purchase Agreement (including any representations or warranties) or affect, modify, expand or supersede any of the rights, obligations or remedies of the Parties. Except as otherwise provided in the immediately preceding sentence, the Parties intend that nothing in the Purchase Agreement contradicts or otherwise limits the terms of this Assignment. However, in the event of any conflict or inconsistency between the terms of the Purchase Agreement and the terms hereof, the terms of the Purchase Agreement shall govern.

[Signature Page Follows]

Page 2 of 3

Intellectual Property to be executed by authorized representatives as of the date first written above. ASSIGNOR: Place/Date: Amplyx Pharmaceuticals, Inc. Address: 66 Mudson Boulevard East New York, NY 10001-2192, United States of America Bv: Name: AMPLEN MURATURE Title: VICE PRESIDENT + SECRETARY Witness: Kalusguli Name: Robert Baxter ASSIGNEE: Place/Date: Basilea Pharmaceutica International AG, Allschwil Address: Hegenheimermattweg 167b, 4123 Allschwil, Switzerland By: By: Name: \_\_\_\_\_ Name: Title: \_\_\_\_\_ Title:

IN WITNESS WHEREOF, the parties hereto have caused this Assignment of Registered

(SIGNATURE PAGE TO ASSIGNMENT OF REGISTERED INTELLECTUAL PROPERTY)

Witness:

Name:

Witness:

Name: \_\_\_\_\_

Intellectual Property to be executed by authorized representative as of the date first written above. **ASSIGNOR:** Place/Date: Amplyx Pharmaceuticals, Inc. Address: 66 Hudson Boulevard East New York, NY 10001-2192, United States of America By: Name: \_\_\_\_\_ Title: Witness:\_\_\_\_\_ Name: **ASSIGNEE:** Place/Date: Basilea Pharmaceutica International AG, Allschwil Address: Hegenheimermattweg 167b, 4123 Allschwil, Switzerland By: By: Name: ---- DocuSigned by: Name: ---- DocuSigned by: Title: Title: Jonathan Thomaste Damian Heller Signer Name: Jonathan Thwaite Signer Name: Damian Heller Signing Reason: I approve this document Signing Reason: I approve this document Signing Time: 10-Nov-2023 | 16:16 CET Signing Time: 10-Nov-2023 | 06:31 PST Witness: 7408F46F531C4E48AAB3106566EA29B3 Witness: <u>E74C452E92B84C5B87C945FD24FEDC5A</u>

IN WITNESS WHEREOF, the parties hereto have caused this Assignment of Registered

Name:

Name:

SCHEDULE A

# REGISTERED IP

04040/A		040407A	040407A		040407A		040407A		040407			040407	Docket Number
710.485	710.485	49748-	49748- 710.485		49748- 710.485		49748- 710.481		49748- 710.102		710.101	49748-	Former Docket Number
Central African Republic - (CF)	(CM)	Cameroon -	Burkina Faso - (BF)		Benin - (BJ)		A.R.I.P.O (AP)	(US)	United States -	(US)	States -	United	Country
1202000193		1202000193	1202000193		1202000193		AP/P/2020/012493		62/649225			62/595894	Application Number
12///2018	î Î	12/7/2018	12/7/2018		12/7/2018		12/7/2018		03/28/2018			12/7/2017	Application Date
(G)	(G)	Issued -	Issued - (G)		Issued - (G)		Allowed - (A)		Lapsed - (L)			Lapsed -	Status
201//		20177	20177		20177								Patent Number
12/14/2021		12/14/2021	12/14/2021		12/14/2021								Grant Date
Amplyx Pharmaceuticals, Inc (AMPLYX)	Pharmaceuticals, Inc (AMPLYX)	(AMPLYX) Amplyx	Amplyx Pharmaceuticals, Inc	Inc (AMPLYX)	Amplyx Pharmaceuticals,	Inc (AMPLYX)	Amplyx Pharmaceuticals,	Inc (AMPLYX)	Amplyx Pharmaceuticals,	Inc (AMPLYX)	Pharmaceuticals,	Amplyx	Owner at PTO

Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number	Grant Date	Owner at PTO
040407A	49748- 710.485	Chad - (TD)	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021	Amplyx Pharmaceuticals, Inc
								(AMPLYX)
040407A	49748- 710.485	Comoro Islands -	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021	Amplyx Pharmaceuticals,
		(KM)			,			Inc (AMPLYX)
040407A	49748- 710 485	Congo - (CG)	1202000193	12/7/2018	Issued -	20177	12/14/2021	Amplyx Pharmaceuticals
					\(\frac{1}{2}\)			Inc
040407A	49748-	Equatorial	1202000193	12/7/2018	Issued -	20177	12/14/2021	Amplyx
	710.485	Guinea -			(G)			Pharmaceuticals,
		(0)						(AMPLYX)
040407A	49748- 710 485	Gabon - (GA)	1202000193	12/7/2018	Issued -	20177	12/14/2021	Amplyx Pharmaceuticals
		`			`			Inc
							1000	(AMPLYX)
040407A	49748- 710.485	Guinea - (GN)	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021	Amplyx Pharmaceuticals,
								$\left \begin{array}{l} \text{Inc} \\ (\text{AMPLYX}) \end{array}\right $
040407A	-84764	Guinea-	1202000193	12/7/2018	Issued -	20177	12/14/2021	Amplyx
	710.485	Bissau - (GW)			(G)			Pharmaceuticals,
		\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \						(AMPLYX)
040407A	49748- 710.485	Ivory Coast - (CI)	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021	Amplyx Pharmaceuticals,
								Inc (AMPLYX)

Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number	Grant Date
040407A	49748- 710.485	Mali - (ML)	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021
040407A	49748- 710.485	Mauritania - (MR)	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021
040407A	49748- 710.485	Niger - (NE)	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021
040407A	49748- 710.485	O.A.P.I	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021
040407A	49748- 710.485	Senegal - (SN)	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021
040407A	49748- 710.485	Togo - (TG)	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021
040407A	49748- 710.591	Eurasian Patent	202091255	12/7/2018	Issued - (G)	202091255	7/27/2023
		Convention - (EA)					
040407A	49748- 710.591	Russian Federation -	202091255	12/7/2018	Issued - (G)	202091255	7/27/2023
		(RU)					

Dacket           Number           040407A           040407A           040407A	Former Docket Number 49748-710.601	Patent Cooperation Treaty - (WO) Belgium - (BE)  Denmark - (DK)	Application Number PCT/US2018/064609 18885399.8 18885399.8	Application Date 12/7/2018 12/7/2018	Lap (L) Issu (G)	Status  Lapsed - (L)  Issued - (G)  Issued - (G)	Patent Number
040407A	49748- 710.611	Denmark - (DK)	18885399.8	12/7/2018	Issued - (G)		3720438
040407A	49748- 710.611	European Patent Convention - (EP)	18885399.8	12/7/2018	Issued - (G)		3720438
040407A	49748- 710.611	Finland - (FI)	18885399.8	12/7/2018	Issued - (G)		3720438
040407A	49748- 710.611	France - (FR)	18885399.8	12/7/2018	Issued - (G)		3720438
040407A	49748- 710.611	Germany - (DE)	18885399.8	12/7/2018	Issued - (G)		602018056721.6
040407A	49748- 710.611	Great Britain - (GB)	18885399.8	12/7/2018	Issued - (G)		3720438

Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number	Grant Date	Owner at PTO
040407A	49748- 710.611	Hong Kong - (HK)	62021027978.7	12/7/2018	Pending - (F)			Amplyx Pharmaceuticals,
								Inc (AMPLYX)
040407A	49748- 710.611	Ireland - (IE)	18885399.8	12/7/2018	Issued - (G)	3720438	8/30/2023	Amplyx Pharmaceuticals,
					,			Inc (AMPLYX)
040407A	49748- 710.611	Italy - (IT)	18885399.8	12/7/2018	Issued - (G)	3720438	8/30/2023	Amplyx Pharmaceuticals.
								Inc (AMPLYX)
040407A	49748- 710.611	Netherlands - (NL)	18885399.8	12/7/2018	Issued - (G)	3720438	8/30/2023	Amplyx Pharmaceuticals,
								lnc (AMPLYX)
040407A	49748- 710.611	Norway - (NO)	18885399.8	12/7/2018	Issued - (G)	3720438	8/30/2023	Amplyx Pharmaceuticals,
								Inc (AMPLYX)
040407A	49748- 710.611	Spain - (ES)	18885399.8	12/7/2018	Issued - (G)	3720438	8/30/2023	Amplyx Pharmaceuticals,
								Inc (AMPLYX)
040407A	49748- 710.611	Sweden - (SE)	18885399.8	12/7/2018	Issued - (G)	3720438	8/30/2023	Amplyx Pharmaceuticals,
								Inc (AMPLYX)
040407A	49748- 710.611	Turkey - (TR)	18885399.8	12/7/2018	Issued - (G)	3720438	8/30/2023	Amplyx Pharmaceuticals,
								Inc (AMPLYX)

Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number	Grant Date
040407A	49748- 710.681	Australia - (AU)	2018379077	12/7/2018	Issued - (G)	2018379077	8/10/2023
040407A	49748-	Brazil -	BR1120200111627	12/7/2018	Exam		
	710.691	(BR)			Requested - (E)		
					`		
040407A	49748- 710.701	Canada - (CA)	3084298	12/7/2018	Pending - (F)		
040407A	49748-	China P.R	201880088941.1	12/7/2018	Issued -	ZL2018800889411	8/1/2023
	710.711	(CN)			(G)		
040407A	49748- 710 731	Israel - (IL)	275121	12/7/2018	Pending -		
	/10./51				(1)		
040407A	49748- 710.741	India - (IN)	202017023152	12/7/2018	Issued - (G)	424223	3/6/2023
040407A	49748-	India - (IN)	202218056260	9/30/2022	Exam		
	710.741				Requested		
					- (E)		
040407A	49748-	Japan - (JP)	2020-550050	12/7/2018	Issued -	7292299	6/8/2023
	710.761				(G)		

Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number	Grant Date	Owner at PTO
040407A	49748-	Japan - (JP)	2023-92871	6/6/2023	Exam			Amplyx
	710.761				Requested			Pharmaceuticals,
					(t)			(AMPLYX)
040407A	49748-	Korea South	10-2020-7019209	12/7/2018	Exam			Amplyx
	710.771	- (KR)			Requested			Pharmaceuticals,
					(t)			(AMPLYX)
040407A	49748- 710 781	Mexico -	MX/a/2020/005927	12/7/2018	Issued -	awaiting	6/14/2023	Amplyx Pharmaceuticals
					`			Inc
								(AMPLYX)
040407A	49748- 710.831	United States -	16/770476	12/7/2018	Issued - (G)	11512079	11/29/2022	Amplyx Pharmaceuticals.
		(US)						Inc
040407B	49748-	United	17/934629	9/23/2022	Published -			Amplyx
	710.831	States -			(P)			Pharmaceuticals,
		(US)						lnc (AMPLYX)
040407A	49748- 710.841	South Africa -	2020/03281	12/7/2018	Issued - (G)	18250/0202	10/25/2023	Amplyx Pharmaceuticals,
		(ZA)						Inc
	10210	¥7 · , 1	(2) 112 1211	0010010	-			(VIAIL PIV)
040408	49748- 711.101	United States -	62/725971	8/31/2018	Lapsed - (L)			Amplyx Pharmaceuticals,
		(US)						Inc (AMPLYX)
040408A	49748-	A.R.I.P.O	AP/P/2021/013039	8/30/2019	Pending -			Amplyx
	711.481	(AP)			(F)			Pharmaceuticals,   Inc
								(AMPLYX)

Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number	Grant Date	Owner at PTO
040408A	49748- 711.485	O.A.P.I (OA)	1202100093	8/30/2019	Issued - (G)	20177	12/14/2021	Amplyx Pharmaceuticals, Inc (AMPLYX)
040408A	49748- 711.591	Eurasian Patent	202190590	8/30/2019	Allowed - (A)			Amplyx Pharmaceuticals,
		Convention - (EA)						Inc (AMPLYX)
040408A	49748- 711.591	Eurasian Patent	202390707	3/27/2023	Published - (P)			Amplyx Pharmaceuticals.
	11.00	Convention - (EA)			(			Inc (AMPLYX)
040408A	49748- 711.601	Patent Cooperation	PCT/US2019/049223	8/30/2019	Lapsed - (L)			Amplyx Pharmaceuticals,
		Treaty - (WO)						Inc (AMPLYX)
040408A	49748- 711.611	European Patent	19853628.6	8/30/2019	Pending - (F)			Amplyx Pharmaceuticals,
		Convention - (EP)						Inc (AMPLYX)
040408A	49748- 711.681	Australia - (AU)	2019328599	8/30/2019	Exam Requested			Amplyx Pharmaceuticals,
					- (E)			Inc (AMPLYX)
040408A	49748-	Brazil -	BR1120210038787	8/30/2019	Exam			Amplyx
	/11.691	(BK)			- (E)			Inc
040408A	49748_	Canada -	3110860	8/30/2019	Pending -			(AMPLYX)
4	711.701	(CA)	1	1	(F)			Pharmaceuticals,
								Inc (AMPLYX)

Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number Grant Date	Owner at PTO
040408A	49748- 711.711	China P.R (CN)	201980072614.1	8/30/2019	Published - (P)		Amplyx Pharmaceuticals,
							Inc (AMPLYX)
040408A	49748- 711.711	Hong Kong - (HK)	62021040416.1	10/14/2021	Published - (P)		Amplyx Pharmaceuticals,
		`			`		Inc (AMPLYX)
040408A	49748-	Israel - (IL)	281140	8/30/2019	Pending -		Amplyx
	711.731				(F)		Pharmaceuticals, Inc
							(AMPLYX)
040408A	49748-	India - (IN)	202117010323	8/30/2019	Exam		Amplyx
	/11./71				- (E)		Inc
							(AMPLYX)
040408A	49748- 711.761	Japan - (JP)	2021-510464	8/30/2019	Pending - (F)		Amplyx Pharmaceuticals.
					,		Inc
040408A	49748-	Korea South	10-2021-7009418	8/30/2019	Exam		Amplyx
	711.771	- (KR)		:	Requested		Pharmaceuticals,
					- (E)		Inc
0/0/08 A	10718	Mavico	VVVCUU/ICUC/9/AVV	8/20/2010	Danding		\\ \mathrace \text{\text{malray}}
040408A	49/48- 711.781	(MX)	NIX/8/2021/002444	8/30/2019	(F)		Pharmaceuticals,
							Inc
							(AMPLYX)
040408A	49748-	United	17/271020	8/30/2019	Pending -		Amplyx
		(US)			``		Inc
							(AMPLYX)

Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number Grant Date	Owner at PTO
040408A	49748- 711.841	South Africa -	2021/01555	8/30/2019	Pending - (F)		Amplyx Pharmaceuticals,
		(ZA)			,		Inc (AMPLYX)
040408A	49748-	Taiwan -	108131566	9/2/2019	Exam		Amplyx
	711.851	(TW)			Requested - (E)		Pharmaceuticals, Inc
					`		(AMPLYX)
040408A	49748-	Argentina -	P190102493	9/2/2019	Published -		Amplyx
	/11.0/1	(AN)			(F)		Inc
							(AMPLYX)
040409	49748- 712.101	United States -	62/689535	6/25/2018	Lapsed -		Amplyx  Pharmaceuticals.
		(US)			`		Inc
040400	10710	T Latted	62/700520	0/04/0010			(AMPLYA)
040409	49/48- 712.102	∪nited States -	62/722539	8/24/2018	Lapsed - (L)		Amplyx Pharmaceuticals,
		(US)					Inc
040409A	49748-	Patent	PCT/US2019/038780	6/24/2019	Lapsed -		Amplyx
	712.601	Cooperation			(L)		Pharmaceuticals,
		(WO)					(AMPLYX)
040409A	49748- 712.611	European Patent	19826531.6	6/24/2019	Pending - (F)		Amplyx Pharmaceuticals.
		Convention					Inc
040400 4	10710	- (EP)	2010204474	6/24/2010	Danding		(AMPLYX)
0+0+07A	712.681	(AU)	2017274474	0/24/2019	(F)		Pharmaceuticals,
							Inc

Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number	Grant Date	Owner at PTO
040409A	49748- 712.701	Canada - (CA)	3104653	6/24/2019	Pending - (F)			Amplyx Pharmaceuticals,
		,						Inc (AMPLYX)
040409A	49748-	China P.R	201980056287.0	6/24/2019	Pending -			Amplyx
	712.711	(CN)			(F)			Pharmaceuticals, Inc
								(AMPLYX)
040409A	49748- 712 761	Japan - (JP)	2020-571542	6/24/2019	Pending -			Amplyx Pharmaceuticals
	1111				(*)			Inc
								(AMPLYX)
040409A	49748- 712 771	Korea South	10-2021-7000794	6/24/2019	Exam			Amplyx
	/12.//1	- (AA)			- (E)			Inc
								(AMPLYX)
040409A	49748-	United	17/253885	6/24/2019	Issued -	11771688	10/3/2023	Amplyx
	712.831	States - (US)			(G)			Pharmaceuticals, Inc
		` '						(AMPLYX)
040410	49748- 714.101	United States -	62/858897	6/7/2019	Lapsed - (L)			Amplyx Pharmaceuticals,
		(US)						Inc
>		1			4			(AMPLYA)
040410A	49748- 714.601	Patent Cooperation	PCT/US2020/036400	6/5/2020	Lapsed - (L)			Amplyx Pharmaceuticals,
		Treaty -						Inc
		(WO)			4			(AMPLYX)
040411	49748- 715 101	United States	62/985274	3/4/2020	Lapsed -			Amplyx
	/13.101	States - (US)			(L)			Inc
								(AMPLYX)

United States -	Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number Grant Date	Owner at PTO
49748-       Australia - 2021230529       3/2/2021       Exam Requested - (E)         49748-       Brazil - 49748-       BR112022017653-8       3/2/2021       Published - (E)         49748-       Canada - 715.601       3174065       3/2/2021       Exam Requested - (E)         49748-       China P.R 202180033043.8       3/2/2021       Published - (E)         49748-       China P.R 202180033043.8       3/2/2021       Published - (E)         49748-       European Pacint Convention - (ED)       21765099.3       3/2/2021       Published - (P)         49748-       Hong Kong Hong G2023074654.2       6/19/2023       Published - (P)         49748-       India - (IN)       202217056899       3/2/2021       Abandoned - (B)	040411A	49748- 715.101	United States - (US)	17/908079	3/2/2021	Published - (P)		Amplyx Pharmaceuticals, Inc
715.601 (AU)  49748- Brazil - BR112022017653-8 3/2/2021 Published - (E)  49748- Canada - 3174065 3/2/2021 Exam 715.601 (CA)  49748- China P.R 202180033043.8 3/2/2021 Published - (E)  49748- European Convention (EP)  49748- Hong Kong 62023074654.2 6/19/2023 Published - (HK)  49748- India - (IN) 202217056899 3/2/2021 Abandoned  715.601 Published - (P)  49748- India - (IN) 202217056899 3/2/2021 Abandoned  715.601 Published - (P)	040411A	49748-	Australia -	2021230529	3/2/2021	Exam		Amplyx
49748- Brazil - BR112022017653-8 3/2/2021 Published - (P)  49748- Canada - 3174065 3/2/2021 Exam 715.601 (CA)  49748- China P.R 202180033043.8 3/2/2021 Published - (E)  715.601 (CN)  49748- European Parent Convention - (EP)  49748- Hong Kong 62023074654.2 6/19/2023 Published - (HK)  49748- India - (IN) 202217056899 3/2/2021 Abandoned  715.601 Parent Convention - (HK)  49748- Hong Kong 62023074654.2 6/19/2023 Published - (P)		715.601	(AU)			Requested - (E)		Pharmaceuticals, Inc
49748- Brazil - BR112022017653-8 3/2/2021 Published - (P)  49748- Canada - 3174065 3/2/2021 Exam 715.601 (CA)  49748- China P.R 202180033043.8 3/2/2021 Published - (E)  49748- European Patent Convention - (EP)  49748- Hong Kong 62023074654.2 6/19/2023 Published - (HK)  49748- India - (IN) 202217056899 3/2/2021 Abandoned  715.601 Patent Convention - (HK)  49748- Hong Kong 62023074654.2 6/19/2023 Published - (P)								(AMPLYX)
49748- Canada - 3174065 3/2/2021 Exam 715.601 (CA) Requested 49748- China P.R 202180033043.8 3/2/2021 Published - 715.601 (CN) Patent 715.601 Patent Convention - (EP) 49748- Hong Kong 62023074654.2 6/19/2023 Published - 715.601 - (HK) 715.601 India - (IN) 202217056899 3/2/2021 Abandoned 715.601 - (B)	040411A	49748- 715.601	Brazil - (BR)	BR112022017653-8	3/2/2021	Published - (P)		Amplyx Pharmaceuticals,
49748- Canada - 3174065 3/2/2021 Exam 715.601 (CA)			`			\		Inc
49748- Canada - 3174065 3/2/2021 Exam 715.601 (CA) 3174065 3/2/2021 Requested 49748- China P.R 202180033043.8 3/2/2021 Published - (E)  49748- European 21765099.3 3/2/2021 Published - (Convention - (EP) 49748- Hong Kong 62023074654.2 6/19/2023 Published - (HK) 6/19/2023 Published - (P)  49748- India - (IN) 202217056899 3/2/2021 Abandoned 715.601 - (B)								(AMPLYX)
49748- China P.R 202180033043.8 3/2/2021 Published - (E) 715.601 (CN)  49748- European 21765099.3 3/2/2021 Published - (P) 715.601 Patent Convention - (EP) 49748- Hong Kong 62023074654.2 6/19/2023 Published - (HK)  49748- India - (IN) 202217056899 3/2/2021 Abandoned 715.601 - (HS)	040411A	49748- 715.601	Canada - (CA)	3174065	3/2/2021	Exam Requested		Amplyx Pharmaceuticals.
49748- China P.R 202180033043.8 3/2/2021 Published - (P)  49748- European 21765099.3 3/2/2021 Published - (P)  715.601 Patent Convention - (EP)  49748- Hong Kong 62023074654.2 6/19/2023 Published - (HK)  715.601 - (HK)  202217056899 3/2/2021 Abandoned - (B)						- (E)		Inc
715.601 (CN) 202180033043.8 3/2/2021 Published - (P)	040411	10710	<u>.</u>	202100020120	2000	<del>-</del> -		(AMPLYX)
49748-       European       21765099.3       3/2/2021       Published -         715.601       Patent Convention - (EP)       (P)         49748-       Hong Kong Hong Kong - (HK)       62023074654.2       6/19/2023       Published - Published	040411A	49748- 715.601	China P.R (CN)	202180033043.8	3/2/2021	Published - (P)		Amplyx Pharmaceuticals,
49748-       European       21765099.3       3/2/2021       Published -         715.601       Patent       (P)         Convention - (EP)       (EP)       (P)         49748-       Hong Kong Hong C2023074654.2       6/19/2023       Published -         715.601       - (HK)       (P)         49748-       India - (IN)       202217056899       3/2/2021       Abandoned - (B)								Inc
715.601 Patent Convention - (EP)  49748- Hong Kong 62023074654.2 6/19/2023 Published - (HK)  715.601 - (HK)  49748- India - (IN) 202217056899 3/2/2021 Abandoned - (B)	040411A	49748-	European	21765099.3	3/2/2021	Published -		Amplyx
Convention - (EP)  49748- Hong Kong 715.601 - (HK)  62023074654.2 6/19/2023 Published - (P)  49748- India - (IN) 202217056899 3/2/2021 Abandoned 715.601		715.601	Patent			(P)		Pharmaceuticals,
49748- 715.601       Hong Kong - (HK)       62023074654.2       6/19/2023       Published - (P)         49748- 715.601       India - (IN)       202217056899       3/2/2021       Abandoned - (B)			Convention - (EP)					Inc
715.601 - (HK) (P)  49748- India - (IN) 202217056899 3/2/2021 Abandoned - (B)	040411A	49748-	Hong Kong	62023074654.2	6/19/2023	Published -		Amplyx
49748- India - (IN) 202217056899 3/2/2021 Abandoned - (B)		715.601	- (HK)			(P)		Pharmaceuticals,
49748- India - (IN) 202217056899 3/2/2021 Abandoned - (B)								(AMPLYX)
- (B)	040411A	49748-	India - (IN)	202217056899	3/2/2021	Abandoned		Amplyx
Inc		715.601				- (B)		Pharmaceuticals,
								(AMPLYX)

Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number Grant Date	Owner at PTO
040411A	49748- 715.601	Israel - (IL)	296093	3/2/2021	Pending - (F)		Amplyx Pharmaceuticals, Inc
040411A	49748- 715.601	Japan - (JP)	2022-552405	3/2/2021	Pending - (F)		Amplyx Pharmaceuticals,
					,		Inc (AMPLYX)
040411A	49748-	Korea South	2022-7034025	3/2/2021	Exam		Amplyx
	/13.601	- (KK)			- (E)		Inc
							(AMPLYX)
040411A	715.601	(MO)			(D)		Pharmaceuticals,
							Inc (AMPLYX)
040411A	49748-	Mexico -	MX/a/2022/010804	3/2/2021	Published -		Amplyx
	715.601	(MX)			(P)		Pharmaceuticals, Inc
							(AMPLYX)
040411A	49748- 715.601	New Zealand -	792042	3/2/2021	Pending - (F)		Amplyx Pharmaceuticals,
		(NZ)					Inc (AMPLYX)
040411A	49748-	Patent	PCT/US2021/020471	3/2/2021	Lapsed -		Amplyx
	715.601	Cooperation   Treaty -			(L)		Pharmaceuticals,
		(WO)					(AMPLYX)
040411A	49748-	Russian	2022123518	3/2/2021	Exam		Amplyx
	/15.601	Federation - (RII)			Requested - (F)		Pharmaceuticals,
							(AMPLYX)

T		I					
Amplyx Pharmaceuticals.		Exam Requested	6/16/2021	2021293911	Australia - (AU)	49748- 716.601	040412A
Inc (AMPLYX)							
Amplyx Pharmaceuticals,		Abandoned - (B)			Argentina - (AR)	49748- 716.601	040412A
Inc (AMPLYX)					(US)		
Amplyx Pharmaceuticals,		Published - (P)	6/16/2021	18/002012	United States -	49748- 716.101	040412A
Inc (AMPLYX)					(US)		
Amplyx Pharmaceuticals,		Lapsed - (L)	6/17/2020	63/040450	United States -	49748- 716.101	040412
Inc (AMPLYX)		- (E)			(AE)		
Amplyx Pharmaceuticals,		Exam Requested	3/2/2021	P6001759/2022	United Arab Emirates -	49748- 715.601	040411A
(AMPLYX)							
Pharmaceuticals,		(F)	0.000	FOEE! 10000	Africa - (ZA)	715.601	0101111
Amplyx		Pending -	3/2/2021	2022/10036	South	49748-	040411A
Inc							
Amplyx Pharmaceuticals,		Pending - (F)	3/2/2021	1120225265/K	Singapore - (SG)	715.601	040411A
(AMPLYX)		:	5		G:		
Inc		(F)			Arabia - (SA)	100.017	
Amplyx		Pending -	3/2/2021	522440394	Saudi	49748-	040411A
Grant Owner at PTO Date	Patent Number G	Status	Application Date	Application Number	Country	Former Docket Number	Docket Number

(AMPLYX)							
Amplyx Pharmaceuticals,		Published - (P)	6/16/2021	10-2023-7001328	Korea South - (KR)	49/48- 716.601	040412A
Inc (AMPLYX)							
Amplyx Pharmaceuticals,		Pending - (F)	6/16/2021	2022-577084	Japan - (JP)	49748- 716.601	040412A
Inc (AMPLYX)							
Amplyx Pharmaceuticals,		Published - (P)	6/16/2021	299057	Israel - (IL)	49748- 716.601	040412A
Inc (AMPLYX)							
Amplyx Pharmaceuticals,		Published - (P)	6/16/2023	62023074617.9	Hong Kong - (HK)	49748- 716.601	040412A
lnc (AMPLYX)					Convention - (EP)		
Amplyx Pharmaceuticals,		Published - (P)	6/16/2021	21825864.8	European Patent	49748- 716.601	040412A
(AMPLYX)							
Amplyx Pharmaceuticals,		Published - (P)	6/16/2021	202180050716.0	China P.R (CN)	49748- 716.601	040412A
(AMPLYX)		(t)					
Pharmaceuticals,		Requested			(CA)	716.601	
Amplyx		Exam	6/16/2021	3187268	Canada -	49748-	040412A
Inc (AMPLYX)							
Pharmaceuticals,		(P)			(BR)	716.601	
Amplyx		Published -	6/16/2021	BR112022024988-8	Brazil -	49748-	040412A
Grant Owner at PTO Date	Patent Number Gr Dr	Status	Application Date	Application Number	Country	Former Docket Number	Docket Number

**RECORDED: 12/12/2023**